Results 81 to 90 of about 13,346 (268)

New cases expand the genotype, phenotype and therapeutic landscape of H syndrome

open access: yes
British Journal of Haematology, EarlyView.
Clément Triaille   +10 more
wiley   +1 more source

Results in pediatric T‐ALL patients treated in trial AIEOP‐BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy

open access: yesHemaSphere, Volume 9, Issue 9, September 2025.
Abstract To improve the outcome of pediatric T‐cell acute lymphoblastic leukemia (T‐ALL) patients, the AIEOP‐BFM ALL 2009 trial modified T‐ALL stratification and treatment based on AIEOP‐BFM ALL 2000 and other pediatric ALL groups' results. This report aims to describe the outcome of T‐ALL patients in trial AIEOP‐BFM ALL 2009 and evaluate prognostic ...
Gunnar Cario   +27 more
wiley   +1 more source

Synchronous neoplasms in a paediatric patient

open access: yesPediatria Polska
Cancer is the second leading cause of death in the paediatric population after injuries. 3–10% of them are multiple primary malignant neoplasms, which are a huge problem both in diagnosis and treatment.
Aleksandra Dembowska   +4 more
doaj   +1 more source

Bagaimana Prognosis Histiocytosis? Sebuah Laporan Kasus [PDF]

open access: yes, 2013
Penderita histiocytosis dengan keterlibatan multiorgan dan disertai gangguan fungsi organ mempunyai prognosis buruk dan tingkat mortalitas tinggi. Dilaporkan seorang penderita histiocytosis, usia 1 tahun 1 bulan yang datang dengan kelainan di kulit ...
Lestari, R. D. (Rini)   +1 more
core  

Diffuse plane xanthomas as the first manifestation of multiple myeloma

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Eleni Koutra   +5 more
wiley   +1 more source

Suspected calcitriol‐mediated hypercalcaemia and postmortem diagnosis of histiocytic sarcoma in a dog

open access: yesVeterinary Record Case Reports, Volume 13, Issue 3, September 2025.
Abstract This report describes a case of refractory ionised hypercalcaemia, of 12 months duration, in an 11‐year‐old, male, neutered beagle diagnosed with metastatic histiocytic sarcoma at postmortem examination. In this case, the parathyroid hormone levels were at the lower end of the reference interval, the parathyroid hormone‐related peptide was ...
Kerry E. Rolph   +5 more
wiley   +1 more source

Histiocytic sarcoma in dogs: epidemiology, anatomopathology, and immunohistochemistry [PDF]

open access: yesPesquisa Veterinária Brasileira
: Histiocytic sarcomas have been described in veterinary medicine since 1980, but studies on the subject are still scarce. Based on this, the objective of this article is to describe the epidemiological, anatomopathological and immunohistochemical ...
Flávia S. Da Luz   +8 more
doaj   +1 more source

Combination of Photodynamic and Bronchoscopic Intervention With Radiation Therapy in Treating Pulmonary Pleomorphic Sarcoma: A Case Report

open access: yesThe Clinical Respiratory Journal, Volume 19, Issue 9, September 2025.
We discuss a case where an innovative combination of photodynamic therapy (PDT) and local radiation therapy to address the diagnostic and therapeutic challenges associated with PPSS resulted in significant improvements in clinical symptoms and patient survival, demonstrating the success of this treatment.
Ran An   +5 more
wiley   +1 more source

An Unusual Case of Cutaneous Langerhans Cell Sarcoma Lacking S100 Expression: A Case Report and Review of the Literature

open access: yesJournal of Cutaneous Pathology, Volume 52, Issue 9, Page 554-567, September 2025.
ABSTRACT Langerhans cell sarcoma (LCS) is a rare neoplastic proliferation of Langerhans cell with aggressive clinical behavior and involves multiple organ systems, including the skin. LCS is characterized by marked cytologic atypia, frequent mitoses including atypical ones, and expression of CD1a, S100, and langerin (CD207).
Randa Obid   +8 more
wiley   +1 more source

History of the rare cancer network and past research. [PDF]

open access: yes, 2014
Approximately, twenty years ago, the Rare Cancer Network (RCN) was formed in Lausanne, Switzerland, to support the study of rare malignancies. The RCN has grown over the years and now includes 130 investigators from twenty-four nations on six continents.
Belkacemi, Y.   +15 more
core   +3 more sources

Home - About - Disclaimer - Privacy